![]() “We see significant potential in this antibody drug conjugate in lung as well as in breast and other cancers that commonly express TROP2,” said Pascal Soriot, Chief Executive Officer, AstraZeneca. As we have done with ENHERTU, we will jointly design and implement strategies to maximize the value of DS-1062.” “This new strategic collaboration with AstraZeneca, a company with extensive experience and significant expertise in the global oncology business, will enable us to deliver DS-1062 to more patients around the world as quickly as possible. “DS-1062, one of our lead DXd ADCs that will form a pillar of our next mid-term business plan, has the potential to become a best-in-class TROP2 ADC in multiple tumors, including lung and breast cancers,” said Sunao Manabe, Representative Director, President and CEO of Daiichi Sankyo Company, Limited. This agreement represents the second global ADC collaboration between the two companies following a similar agreement in March 2019 for Daiichi Sankyo’s ENHERTU®, a HER2 directed DXd ADC. Daiichi Sankyo will manufacture and supply DS-1062. Tokyo, Munich and Basking Ridge, NJ – (July 27, 2020) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced today that it has entered into a global development and commercialization agreement with AstraZeneca (LSE, STO, NYSE: AZN) for Daiichi Sankyo’s DS-1062, a TROP2 directed DXd antibody drug conjugate (ADC), currently in phase 1 clinical development for non-small cell lung cancer (NSCLC) and triple negative breast cancer (TNBC).ĭaiichi Sankyo and AstraZeneca will jointly develop and commercialize DS-1062 worldwide, except in Japan where Daiichi Sankyo will maintain exclusive rights. AstraZeneca to pay Daiichi Sankyo up to $6 billion in total consideration, including a $1 billion upfront payment and up to an additional $5 billion contingent upon achievement of future regulatory and sales milestones.Agreement represents second collaboration between Daiichi Sankyo and AstraZeneca for a Daiichi Sankyo DXd antibody drug conjugate (ADC).Daiichi Sankyo and AstraZeneca Enter New Global Development and Commercialization Collaboration for Daiichi Sankyo’s ADC DS-1062 Vice President, Corporate Communications Department Please address inquiries to Junichi Onuma, ![]() (Code no.: 4568, First Section, Tokyo Stock Exchange) Representative: Sunao Manabe, Representative Director, President and CEO ![]() The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.Company name: DAIICHI SANKYO COMPANY, LIMITED The data will be presented at a forthcoming medical meeting and shared with health authorities.įor More Such Health News, visit These first Phase III trial results from the datopotamab deruxtecan clinical programme provide compelling evidence for the potential role this TROP2-directed antibody drug conjugate can play in treating patients with lung cancer." Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca, said, "With TROPION-Lung01, we met the dual primary endpoint of progression-free survival, challenging the entrenched standard of care in a previously treated and unselected patient population that has long deserved an alternative to chemotherapy. In the trial, datopotamab deruxtecan's safety profile was consistent with previous clinical trials with no new safety signals identified. For this, the data were not mature and an early trend was observed in favour of datopotamab deruxtecan versus docetaxel that did not meet the prespecified threshold for statistical significance at this interim analysis. ![]() The company said the trial will continue to assess the dual primary endpoint of overall survival. This was compared to docetaxel, the current standard of care chemotherapy. In the trial, Datopotamab deruxtecan met dual primary endpoint of statistically significant improvement in progression-free survival in previously treated locally advanced or metastatic disease. It is designed using Daiichi Sankyo's proprietary DXd ADC technology. (RTTNews) - British drug major AstraZeneca plc (AZN, AZN.L) announced Monday positive high-level results from the TROPION-Lung01 Phase III trial of datopotamab deruxtecan (Dato-DXd) in patients with advanced non-small cell lung cancer.ĭatopotamab deruxtecan is a specifically engineered TROP2-directed DXd antibody drug conjugate or ADC being jointly developed by AstraZeneca and Daiichi Sankyo.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |